IP Library Granted Patent US 11,298,517
Granted Patent B2
US 11,298,517 · App. 16/251,553 · Granted Apr 12, 2022

Advanced functional biocompatible foam used as a hemostatic agent for non-compressible acute wounds

Inventors: Matthew Dowling (Washington, DC); Srinivasa R. Raghavan (Silver Spring, MD)
Assignee: University of Maryland, College Park
A61M35/003A61L24/0026A61L26/0076A61L2400/04
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,298,517
App. No.
16/251,553
Granted
Apr 12, 2022
Kind
B2
Abstract

A sprayable polymeric foam hemostat for both compressible and non-compressible (intracavitary) acute wounds is disclosed. The foam comprises hydrophobically-modified polymers, such as hm-chitosan, or other amphiphilic polymers that anchor themselves within the membrane of cells in the vicinity of the wound. By rapidly expanding upon being released from a canister pressurized with liquefied gas propellant, the foam is able to enter injured body cavities and staunch bleeding. The seal created is strong enough to substantially prevent the loss of blood from these cavities. Hydrophobically-modified polymers inherently prevent microbial infections and are suitable for oxygen transfer required during normal wound metabolism. The amphiphilic polymers form solid gel networks with blood cells to create a physical clotting mechanism that prevent loss of blood.

Claims (9)

1. A method for treating a cavity wound including a non-compressible hemorrhage, comprising applying a hydrophobically-modified chitosan composition to a cavity wound including a non-compressible hemorrhage, wherein:

the hydrophobically-modified chitosan composition does not comprise proteins involved in the accelerated formation of fibrin networks, and the composition comprises a foaming agent to foam and expand in the cavity and effect hemostasis with the hydrophobically modified chitosan; the hydrophobically-modified chitosan comprising hydrophobic substituents having from 8 to 24 carbon atoms so as to form a gel-like hemostatic network.

2. The method of claim 1 , wherein the foaming agent is selected from sodium lauryl sulfate and sodium oleate.

3. The method of claim 1 , wherein the composition further comprises one or more plasticizers selected from glycerol, glycerophosphate, polyethylene glycol, polyethylene oxide, tripolyphosphate, polycaprolactone, polyurethane, and silicone.

4. The method of claim 3 , wherein hydropobically modified chitosan composition has a ratio of chitosan:plasticizer of 80:20 by weight.

5. The method of claim 1 , wherein the hydrophobic substituents are alkanes.

6. The method of claim 1 , wherein the hydrophobically modified chitosan has a concentration of 0.1% to 2.0% by weight.

7. The method of claim 1 , wherein the hydrophobic modification of the chitosan is of 1 to 100 moles of a hydrophobic substituent per 1 mole of Chitosan.

8. The method of claim 1 , wherein the hydrophobically modified composition further comprises one or more anti-bacterial compounds selected from ampicillin, penicillin, bactroban, bacitracin, mupirocin, neomycin, vanomycin, ponericin G1, norfloxacin, and silver.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 3, 2020
From: RAGHAVAN, SRINIVASA; DOWLING, MATTHEW
To: UNIVERSITY OF MARYLAND, COLLEGE PARK
Reel/Frame 052829/0891 →
Continuity (5)
Continuation 15443009 · Feb 27, 2017
Continuation 14200691 · Mar 7, 2014
Continuation 12946818 · Nov 15, 2010
Provisional Application 61261194 · Nov 13, 2009
Related Publication 20190192839A1 · Jun 27, 2019
Cited By (2)
US 12,201,742 US 12,403,157